Scientists have stumbled onto a hint that measuring a toxic protein tied to Alzheimer's disease just might one day be useful in diagnosing a different brain disease in football players and others who have suffered repeated blows to the head. The findings were published late Friday by the medical journal JAMA and presented at a scientific meeting in Japan.

Doctors currently evaluate symptoms such as mood swings and memory loss to try to tell if patients may have CTE, or chronic traumatic encephalopathy, a disease linked to concussions and other brain trauma. But other diseases cause similar symptoms, and a CTE diagnosis can only be confirmed by examining the brain after death. That gap has long frustrated doctors, patients and families.

The new clue involves a protein called tau, which normally supports neurons but becomes abnormal in Alzheimer's disease, tangling inside those nerve cells. Researchers at Washington University in St. Louis were using autopsy samples to study a tau fragment called eMTBR-tau243, which may help track those tangles, when they found something unusual: a patient with high levels of that biomarker even though records showed the person did not have Alzheimer's but advanced CTE instead.

The researchers turned to a larger collection of autopsied brain and other samples, and eventually tested blood stored from 11 people who had been classified as having CTE. Compared to healthy people, levels of eMTBR-tau243 were higher in those with advanced CTE, said study coauthor Chihiro Sato, a Washington University assistant professor of neurology. The biomarker could not reliably identify early-stage CTE.

Preliminary, but promising

Independent experts urged caution. It is an interesting but very preliminary finding, requiring far larger studies to see if there is a real connection, cautioned Dr Rudolph Castellani, a neuropathologist at Northwestern University who was not involved with the research.

Abnormal tau is found in several brain diseases, many of which can overlap in older adults, adding to the difficulty in teasing apart its role in any one disease, including CTE. Sato, who studies such tau-related diseases, also stressed that much more research is needed before the finding can be put to clinical use.

The small size of the blood sample, 11 people classified as having CTE, is one reason for caution. A biomarker that works in a small group may not hold up when tested in larger and more varied populations, and it may behave differently in people at earlier stages of the disease.

Why a living diagnosis matters

A reliable way to diagnose CTE in living people would change how the disease is studied and treated. At present, researchers can only confirm CTE after death, which makes it hard to track how the disease progresses, to test treatments, or to give patients and families a clear answer about their symptoms.

Football players, boxers, military veterans and others exposed to repeated head impacts are among those at risk. For them, a blood test that could detect CTE during life would be a major step, even if it is still years away from routine use.

For now, the tau fragment remains a clue rather than a test. The researchers and independent experts agree on the next step: far larger studies to find out whether the connection between eMTBR-tau243 and CTE is real, and whether it can ever help doctors diagnose the disease in the living.